108 related articles for article (PubMed ID: 38820067)
1. Transcriptome and metabolome sequencing identifies glutamate and LPAR1 as potential factors of anlotinib resistance in thyroid cancer.
Liu B; Peng Y; Su Y; Diao C; Qian J; Zhan X; Cheng R
Anticancer Drugs; 2024 Jun; ():. PubMed ID: 38820067
[TBL] [Abstract][Full Text] [Related]
2. Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells.
Lu J; Xu W; Qian J; Wang S; Zhang B; Zhang L; Qiao R; Hu M; Zhao Y; Zhao X; Han B
BMC Med Genomics; 2019 Mar; 12(Suppl 2):38. PubMed ID: 30871526
[TBL] [Abstract][Full Text] [Related]
3. Integration of transcriptomics and metabolomics reveals anlotinib-induced cytotoxicity in colon cancer cells.
Jia Z; Zhang Z; Tian Q; Wu H; Xie Y; Li A; Zhang H; Yang Z; Zhang X
Gene; 2021 Jun; 786():145625. PubMed ID: 33798683
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma.
Xu J; Chen C; Sun K; Shi Q; Wang B; Huang Y; Ren T; Tang X
Front Oncol; 2023; 13():1192472. PubMed ID: 37404767
[TBL] [Abstract][Full Text] [Related]
5. TGF-β Signaling Activation Confers Anlotinib Resistance in Gastric Cancer.
Chen J; Hai Y; Hu Q; Chen C; Jiang X; Gao Y
Pharm Res; 2023 Mar; 40(3):689-699. PubMed ID: 36539669
[TBL] [Abstract][Full Text] [Related]
6. Anlotinib Exerts Inhibitory Effects against Cisplatin-Resistant Ovarian Cancer In Vitro and In Vivo.
Ji Y; Li X; Qi Y; Zhao J; Zhang W; Qu P
Molecules; 2022 Dec; 27(24):. PubMed ID: 36558006
[TBL] [Abstract][Full Text] [Related]
7. Transcriptome profiling analysis reveals that ATP6V0E2 is involved in the lysosomal activation by anlotinib.
Sun X; Shu Y; Yan P; Huang H; Gao R; Xu M; Lu L; Tian J; Huang D; Zhang J
Cell Death Dis; 2020 Aug; 11(8):702. PubMed ID: 32839434
[TBL] [Abstract][Full Text] [Related]
8. Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC.
Wang S; Lou N; Luo R; Hao X; Liu Y; Wang L; Shi Y; Han X
J Transl Med; 2022 May; 20(1):248. PubMed ID: 35642002
[TBL] [Abstract][Full Text] [Related]
9. Chromatin accessibility analysis reveals that TFAP2A promotes angiogenesis in acquired resistance to anlotinib in lung cancer cells.
Zhang LL; Lu J; Liu RQ; Hu MJ; Zhao YM; Tan S; Wang SY; Zhang B; Nie W; Dong Y; Zhong H; Zhang W; Zhao XD; Han BH
Acta Pharmacol Sin; 2020 Oct; 41(10):1357-1365. PubMed ID: 32415222
[TBL] [Abstract][Full Text] [Related]
10. Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line.
Lu J; Shi Q; Zhang L; Wu J; Lou Y; Qian J; Zhang B; Wang S; Wang H; Zhao X; Han B
Front Oncol; 2019; 9():886. PubMed ID: 31572680
[TBL] [Abstract][Full Text] [Related]
11. Identification of biomarkers and key pathways in synovial sarcoma cells exposed to anlotinib by integrating bioinformatics analysis and experimental validation.
Liu X; Fu M; Jia C; Wang X; Song Y; Peng C
Am J Transl Res; 2022; 14(10):6906-6923. PubMed ID: 36398254
[TBL] [Abstract][Full Text] [Related]
12. [Mechanism of nuclear protein 1 in the resistance to axitinib in clear cell renal cell carcinoma].
Liu YC; Wu ZL; Ge LY; DU T; Wu YQ; Song YM; Liu C; Ma LL
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 55(5):781-792. PubMed ID: 37807730
[TBL] [Abstract][Full Text] [Related]
13. β-Sitosterol attenuates anlotinib resistance in non-small cell lung cancer cells by inhibiting miR-181a-3p/SHQ1 signaling.
Wang LH; Sun YH; Liu H; Yang X; Wen Z; Tian XF
Chem Biol Drug Des; 2024 Mar; 103(3):e14493. PubMed ID: 38439529
[TBL] [Abstract][Full Text] [Related]
14. A Serum Metabolomic Study Reveals Changes in Metabolites During the Treatment of Lung Cancer-Bearing Mice with Anlotinib.
Pan X; Chen W; Nie M; Liu Y; Xiao Z; Zhang Y; Zhang W; Zou X
Cancer Manag Res; 2021; 13():6055-6063. PubMed ID: 34377024
[TBL] [Abstract][Full Text] [Related]
15. Silencing TRIM29 Sensitizes Non-small Cell Lung Cancer Cells to Anlotinib by Promoting Apoptosis
Wu M; Jin MM; Cao XH; Zhao L; Li YH
Curr Cancer Drug Targets; 2024; 24(4):445-454. PubMed ID: 37644752
[TBL] [Abstract][Full Text] [Related]
16. Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer
Li T; Qian Y; Zhang C; Uchino J; Provencio M; Wang Y; Shi X; Zhang Y; Zhang X
Transl Lung Cancer Res; 2021 Apr; 10(4):1873-1888. PubMed ID: 34012799
[TBL] [Abstract][Full Text] [Related]
17. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
[TBL] [Abstract][Full Text] [Related]
18. An Integrative Metabolomic and Network Pharmacology Study Revealing the Regulating Properties of Xihuang Pill That Improves Anlotinib Effects in Lung Cancer.
Li C; Wang Z; Chen W; Cao B; Zhang M; Gu Q; Qi S; Fei X; Shi Y; Li X; Li R; Wang J; Li G
Front Oncol; 2021; 11():697247. PubMed ID: 34434895
[TBL] [Abstract][Full Text] [Related]
19. SOD2 confers anlotinib resistance via regulation of mitochondrial damage in OSCC.
Li S; Cao C; Huang Z; Tang D; Chen J; Wang A; He Q
Oral Dis; 2024 Mar; 30(2):281-291. PubMed ID: 36229195
[TBL] [Abstract][Full Text] [Related]
20. Metabolic reprogramming driven by METTL1-mediated tRNA m7G modification promotes acquired anlotinib resistance in oral squamous cell carcinoma.
Chen J; Zhou Q; Li S; Ling R; Zhao Y; Chen D; Wang A; Cao Y
Transl Res; 2024 Jun; 268():28-39. PubMed ID: 38280546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
